| Literature DB >> 30084271 |
Cevdet Ozdemir1, Umut Can Kucuksezer2, Mubeccel Akdis3, Cezmi A Akdis3.
Abstract
INTRODUCTION: Asthma, a common, non-communicable chronic disease affects over 300 million individuals worldwide. The Western world lifestyle is claimed to be responsible for this high and increasing prevalence. Asthma has been defined as a syndrome with various phenotypes and endotypes, allergic asthma and type 2 asthma being the most frequent. A great increase in prevalence of allergic diseases has necessitated intensive investigations both for understanding the underlying mechanisms and for the development of novel therapy options with long-term efficacy and limited side-effects. Allergic patients demonstrate unique presentations with variable visible characteristics and disease outcomes depending on different molecular mechanisms, related to influence of genes and epigenetic control by micro- and macro-environment. Areas covered: This article reviews the definition of asthma phenotypes and possible endotypes, advances in allergy-immunology field and contemporary personalized therapy options for asthma. Expert commentary: Better understanding of the complex immune network of allergic inflammation and key players of immunity is continuously being provided for clarification of asthma sub-types. Successful therapy of asthma requires better definition of underlying pathogenesis, which sequentially could end up with 'custom-tailored' individualized, evidence-based and more precise therapy options; a new era termed as 'precision medicine'. Endotype, phenotype, theratype and biomarker terms arise as major keywords in precision/personalized medicine.Entities:
Keywords: Allergy; asthma; biomarker; endotype; genotype; phenotype; precision medicine; theratype
Mesh:
Substances:
Year: 2018 PMID: 30084271 DOI: 10.1080/17476348.2018.1505507
Source DB: PubMed Journal: Expert Rev Respir Med ISSN: 1747-6348 Impact factor: 3.772